Lian Tian1, Danchen Wu1, Asish Dasgupta1, Kuang-Hueih Chen1, Jeffrey Mewburn1, Francois Potus1, Patricia D A Lima2, Zhigang Hong3, Yuan-Yuan Zhao4, Charles C T Hindmarch2, Shelby Kutty5, Steeve Provencher6, Sebastien Bonnet6, Gopinath Sutendra7, Stephen L Archer1,2. 1. From the Department of Medicine (L.T., D.W., A.D., K.-H.C., J.M., F.P., S.L.A.), Queen's University, Kingston, Ontario, Canada. 2. Queen'ps CardioPulmonary Unit, Department of Medicine, Translational Institute of Medicine (P.D.A.L., C.C.T.H., S.L.A.), Queen's University, Kingston, Ontario, Canada. 3. Department of Pharmacology, University of Illinois at Chicago (Z.H.). 4. Department of Agricultural, Food and Nutritional Science (Y.-Y.Z.), University of Alberta, Edmonton, Canada. 5. Department of Medicine, John Hopkins University, Baltimore, MD (S.K.). 6. Pulmonary Hypertension Research Group, Department of Medicine, Heart and Lung Institute of Quebec, Laval University, Canada (S.P., S.B.). 7. Department of Medicine (G.S.), University of Alberta, Edmonton, Canada.
Abstract
RATIONALE: Right ventricular (RV) fibrosis in pulmonary arterial hypertension contributes to RV failure. While RV fibrosis reflects changes in the function of resident RV fibroblasts (RVfib), these cells are understudied. OBJECTIVE: Examine the role of mitochondrial metabolism of RVfib in RV fibrosis in human and experimental pulmonary arterial hypertension. METHODS AND RESULTS: Male Sprague-Dawley rats received monocrotaline (MCT; 60 mg/kg) or saline. Drinking water containing no supplement or the PDK (pyruvate dehydrogenase kinase) inhibitor dichloroacetate was started 7 days post-MCT. At week 4, treadmill testing, echocardiography, and right heart catheterization were performed. The effects of PDK activation on mitochondrial dynamics and metabolism, RVfib proliferation, and collagen production were studied in RVfib in cell culture. Epigenetic mechanisms for persistence of the profibrotic RVfib phenotype in culture were evaluated. PDK expression was also studied in the RVfib of patients with decompensated RV failure (n=11) versus control (n=7). MCT rats developed pulmonary arterial hypertension, RV fibrosis, and RV failure. MCT-RVfib (but not left ventricular fibroblasts) displayed excess mitochondrial fission and had increased expression of PDK isoforms 1 and 3 that persisted for >5 passages in culture. PDK-mediated decreases in pyruvate dehydrogenase activity and oxygen consumption rate were reversed by dichloroacetate (in RVfib and in vivo) or siRNA targeting PDK 1 and 3 (in RVfib). These interventions restored mitochondrial superoxide and hydrogen peroxide production and inactivated HIF (hypoxia-inducible factor)-1α, which was pathologically activated in normoxic MCT-RVfib. Redox-mediated HIF-1α inactivation also decreased the expression of TGF-β1 (transforming growth factor-beta-1) and CTGF (connective tissue growth factor), reduced fibroblast proliferation, and decreased collagen production. HIF-1α activation in MCT-RVfib reflected increased DNMT (DNA methyltransferase) 1 expression, which was associated with a decrease in its regulatory microRNA, miR-148b-3p. In MCT rats, dichloroacetate, at therapeutic levels in the RV, reduced phospho-pyruvate dehydrogenase expression, RV fibrosis, and hypertrophy and improved RV function. In patients with pulmonary arterial hypertension and RV failure, RVfib had increased PDK1 expression. CONCLUSIONS: MCT-RVfib manifest a DNMT1-HIF-1α-PDK-mediated, chamber-specific, metabolic memory that promotes collagen production and RV fibrosis. This epigenetic mitochondrial-metabolic pathway is a potential antifibrotic therapeutic target.
RATIONALE: Right ventricular (RV) fibrosis in pulmonary arterial hypertension contributes to RV failure. While RV fibrosis reflects changes in the function of resident RV fibroblasts (RVfib), these cells are understudied. OBJECTIVE: Examine the role of mitochondrial metabolism of RVfib in RV fibrosis in human and experimental pulmonary arterial hypertension. METHODS AND RESULTS: Male Sprague-Dawley rats received monocrotaline (MCT; 60 mg/kg) or saline. Drinking water containing no supplement or the PDK (pyruvate dehydrogenase kinase) inhibitor dichloroacetate was started 7 days post-MCT. At week 4, treadmill testing, echocardiography, and right heart catheterization were performed. The effects of PDK activation on mitochondrial dynamics and metabolism, RVfib proliferation, and collagen production were studied in RVfib in cell culture. Epigenetic mechanisms for persistence of the profibrotic RVfib phenotype in culture were evaluated. PDK expression was also studied in the RVfib of patients with decompensated RV failure (n=11) versus control (n=7). MCTrats developed pulmonary arterial hypertension, RV fibrosis, and RV failure. MCT-RVfib (but not left ventricular fibroblasts) displayed excess mitochondrial fission and had increased expression of PDK isoforms 1 and 3 that persisted for >5 passages in culture. PDK-mediated decreases in pyruvate dehydrogenase activity and oxygen consumption rate were reversed by dichloroacetate (in RVfib and in vivo) or siRNA targeting PDK 1 and 3 (in RVfib). These interventions restored mitochondrial superoxide and hydrogen peroxide production and inactivated HIF (hypoxia-inducible factor)-1α, which was pathologically activated in normoxic MCT-RVfib. Redox-mediated HIF-1α inactivation also decreased the expression of TGF-β1 (transforming growth factor-beta-1) and CTGF (connective tissue growth factor), reduced fibroblast proliferation, and decreased collagen production. HIF-1α activation in MCT-RVfib reflected increased DNMT (DNA methyltransferase) 1 expression, which was associated with a decrease in its regulatory microRNA, miR-148b-3p. In MCTrats, dichloroacetate, at therapeutic levels in the RV, reduced phospho-pyruvate dehydrogenase expression, RV fibrosis, and hypertrophy and improved RV function. In patients with pulmonary arterial hypertension and RV failure, RVfib had increased PDK1 expression. CONCLUSIONS:MCT-RVfib manifest a DNMT1-HIF-1α-PDK-mediated, chamber-specific, metabolic memory that promotes collagen production and RV fibrosis. This epigenetic mitochondrial-metabolic pathway is a potential antifibrotic therapeutic target.
Authors: Weiling Xu; Thomas Koeck; Abigail R Lara; Donald Neumann; Frank P DiFilippo; Michelle Koo; Allison J Janocha; Fares A Masri; Alejandro C Arroliga; Constance Jennings; Raed A Dweik; Rubin M Tuder; Dennis J Stuehr; Serpil C Erzurum Journal: Proc Natl Acad Sci U S A Date: 2007-01-16 Impact factor: 11.205
Authors: Baohua Jiang; Yupu Deng; Colin Suen; Mohamad Taha; Ketul R Chaudhary; David W Courtman; Duncan J Stewart Journal: Am J Respir Cell Mol Biol Date: 2016-04 Impact factor: 6.914
Authors: Glenn Marsboom; Christian Wietholt; Chad R Haney; Peter T Toth; John J Ryan; Erik Morrow; Thenappan Thenappan; Peter Bache-Wiig; Lin Piao; Jonathan Paul; Chin-Tu Chen; Stephen L Archer Journal: Am J Respir Crit Care Med Date: 2012-01-12 Impact factor: 21.405
Authors: Glenn Marsboom; Peter T Toth; John J Ryan; Zhigang Hong; Xichen Wu; Yong-Hu Fang; Thenappan Thenappan; Lin Piao; Hannah J Zhang; Jennifer Pogoriler; Yimei Chen; Erik Morrow; E Kenneth Weir; Jalees Rehman; Stephen L Archer Journal: Circ Res Date: 2012-04-17 Impact factor: 17.367
Authors: Debra F Higgins; Mangatt P Biju; Yasuhiro Akai; Anton Wutz; Randall S Johnson; Volker H Haase Journal: Am J Physiol Renal Physiol Date: 2004-08-17
Authors: Mark K Friedberg; Mi-Young Cho; Jing Li; Renato S Assad; Mei Sun; Sagar Rohailla; Osami Honjo; Christian Apitz; Andrew N Redington Journal: Am J Respir Cell Mol Biol Date: 2013-12 Impact factor: 6.914
Authors: Valentina Masola; Mario Bonomini; Silvio Borrelli; Lorenzo Di Liberato; Luigi Vecchi; Maurizio Onisto; Giovanni Gambaro; Roberto Palumbo; Arduino Arduini Journal: Int J Mol Sci Date: 2022-04-27 Impact factor: 6.208
Authors: Alan J Mouton; Elizabeth R Flynn; Sydney P Moak; Nikaela M Aitken; Ana C M Omoto; Xuan Li; Alexandre A da Silva; Zhen Wang; Jussara M do Carmo; John E Hall Journal: J Mol Cell Cardiol Date: 2021-05-21 Impact factor: 5.763